David Altshuler, EVP, Global Research and CSO at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 12,448 shares at $425.70 ($5.3M) on 2024-02-26, disclosed to the SEC on 2024-02-27.
Scheduled sale ($5.3M) by EVP, Global Research and CSO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $431.79 | 3,970 | $1.7M | 32.2% |
| 2 | $425.70 | 4,239 | $1.8M | 33.9% |
| 3 | $425.70 | 4,239 | $1.8M | 33.9% |
| Total | $427.64 avg | 12,448 | $5.3M | 100% |
| Filing → |
| VRTX | SELL | 2025-03-12 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-03-05 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-02-28 | $611K | — | Filing → |